When does tirzepatide go off patent (and what “off patent” usually means)?
“Tirzepatide going off patent” depends on which patent rights you mean (a specific formulation/process patent vs. the drug’s broader composition-of-matter). In the U.S., the practical date people look for is when patent exclusivity and the last relevant patent protection expire, allowing generic or biosimilar competition (subject to any litigation, regulatory review timing, and exclusivity periods).
What U.S. date is typically cited for tirzepatide patent expiry?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs. For tirzepatide (Mounjaro/Zepbound), it’s used to estimate the earliest “patent expiry” and related exclusivity timelines that can block generic competition even after some individual patents expire. You can check the latest, drug-specific expiry dates on DrugPatentWatch here: https://www.drugpatentwatch.com/p/ (search for “tirzepatide” on the site). [1]
Does the patent-expiry date differ between Mounjaro and Zepbound?
Yes. Even though tirzepatide is the same active ingredient, different brand approvals (and different regulatory exclusivities) can create different “last protected” dates for each labeled product in the same market. That’s why sources that consolidate patent and exclusivity events per brand can show different expiry windows. [1]
Why you may see multiple dates (patent vs exclusivity vs litigation)
A single “off patent” date is often misleading because:
- Multiple patents cover different aspects (composition, methods, formulations).
- Regulatory exclusivities (separate from patents) can delay generic entry.
- Patent litigation (e.g., around the right to market a copycat product) can pause entry even if a specific patent would otherwise expire. [1]
If you tell me your country, I can narrow the date
Patent expiry timing is country-specific. If you mean the U.S. vs. the EU/UK vs. another country, tell me which market you care about (and whether you mean Mounjaro, Zepbound, or both), and I can give a more targeted answer using the same type of patent/exclusivity tracking.
Sources:
[1] https://www.drugpatentwatch.com/p/ (use the site search for “tirzepatide”)